Pfizer Inc. (PFE) said it has suspended the osteoarthritis clinical program for the investigational compound tanezumab, effective immediately, following a request by the FDA.
The worldwide suspension follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.
The clinical hold includes both the suspension of recruitment of new patients and the dosing of existing patients in the osteoarthritis program, as well as patients with osteoarthritis in other studies.
The FDA has asked the company to present its assessment of the potential implications of the adverse events in the osteoarthritis program for the other tanezumab clinical programs involving non-osteoporosis patients.
The company is actively working with the FDA, to determine the appropriate course of action, which will serve the best interest of patients.
For comments and feedback contact: editorial@rttnews.com
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.